Modi Venture Partners
ActiveOverview
Modi Ventures is an early-stage venture capital firm founded in 2022 that invests at the intersection of technology and biology, with a focus on the emerging bioeconomy. The firm specializes in funding technology platforms designed to enhance health outcomes, with particular emphasis on artificial intelligence, microfluidics, multiomics, precision medicine, synthetic biology, gene editing, and living therapies. Modi Ventures operates from TMC Helix Park within the Texas Medical Center in Houston and manages approximately $134 million in assets under management across two funds.
History
Modi Ventures was founded in 2022 and launched its operations in 2023. The firm closed its first fund, Tech+Bio Fund I, at $32 million in 2023, establishing its initial investment vehicle. In July 2025, Modi Ventures raised its second fund, Fund II, at $88 million in an oversubscribed round, demonstrating strong institutional confidence in the firm's investment thesis and strategy.
Product Lines
| Product Line | Positioning | Price Range |
|---|---|---|
| Tech+Bio Fund I | Early-stage biotech and healthcare investments | $32 million fund size |
| Tech+Bio Fund II | Early-stage biotech and healthcare investments | $88 million fund size |
Manufacturing
As a venture capital firm, Modi Ventures does not manufacture physical products. Instead, it provides capital and strategic mentorship to portfolio companies developing technology platforms in biotech and healthcare sectors.
Notable Products
- Komo Biosciences - Portfolio company accelerating therapeutic development through high-efficiency integrases
- UnNatural Products - Portfolio company engineering synthetic molecules to create drugs targeting traditionally undruggable targets
Reputation
Modi Ventures is recognized for its specialized focus on the technology-biology intersection within the emerging bioeconomy, distinguishing it from broader venture capital firms. The firm has established credibility through partnerships with notable co-investors including Khosla Ventures and Section 32, and its location within the Texas Medical Center provides access to a significant medical and research ecosystem. The firm's early-stage investment strategy and commitment to mentoring founders reflects a hands-on approach to portfolio development, though as a relatively young firm founded in 2022, its long-term track record remains limited.